Table 2.

Quality assessment of studies included in systematic review of antidepressant effects of ginsenosides following modified scale of CAMARADES

First author, year	1	2	3	4	5	6	7	8	9	10	Quality score
Chen 2019 [30]	√	√	√		√	√		√	√	√	8
Cui 2012 [31]	√	√	√		√	√		√	√	√	8
Duong 2016 [32]	√	√	√		√	√		√	√	√	8
Fan 2018a [37]	√	√			√	√		√	√	√	7
Fan 2018b [38]	√					√		√	√	√	5
Huang 2013 [42]	√	√	√			√		√			5
Jiang 2012 [23]	√	√			√	√		√	√	√	7
Jin 2017 [43]	√	√			√	√		√	√	√	7
Kang 2017 [29]	√	√			√	√		√	√	√	7
Kim 2019 [22]	√	√	√					√	√	√	6
Lee 2012 [40]	√	√	√			√		√	√	√	7
Liu 2016 [36]	√	√			√	√		√	√	√	7
Mou 2017 [41]	√	√	√			√		√	√	√	7
Ren 2017 [24]	√	√			√	√		√	√	√	7
Wang 2017 [33]	√	√	√		√	√		√	√	√	8
Wu 2012 [44]	√	√	√			√		√			5
Xu 2017 [27]	√	√			√	√		√	√	√	7
Yao 2012 [28]	√	√	√		√	√		√	√		7
You 2017 [25]	√	√			√	√		√	√	√	7
Yu 2018 [39]	√		√		√	√		√	√	√	7
Zhang 2017 [26]	√	√	√			√		√	√	√	7
Zheng 2014 [35]	√	√	√			√		√	√	√	7
Zhu 2016 [34]	√	√	√		√	√		√	√	√	8

Studies fulfilling the criteria of: (1) peer reviewed publication; (2) control of temperature; (3) random allocation to groups; (4) blinded induction of depression; (5) blinded assessment of behavioral outcome; (6) use of anesthetic without significant intrinsic neuroprotective activity; (7) calculation of the sample size necessary to achieve sufficient power; (8) appropriate animal model which uses animals without relevant comorbidities (aged, diabetic, or hypertensive); (9) compliance with animal welfare regulations; (10) statement of potential conflict of interest.